Luis Gonzalez-Mendoza
Pediatric Endocrinology · Miami, FLNPI 1447324744
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,423 of the $8,656 with a category attached, or 62.6%. 34 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 38.8% of the total. Reporting peaked in 2019 at $4,285 and has fallen 81.3% since, to $801 in 2025.
Across 213 payments — averaging $40.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$3K
- Insulet Corporation$688
- Tandem Diabetes Care, Inc.$544
- AbbVie$519
- Novo Nordisk$507
- Ascendis Pharma Endocrinology Inc$360
- plus $3K from 28 others
Across 12 payments — averaging $2194.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$16K
- Eli Lilly$11K
What the payments were for
- Consulting fees$2,24026%
- Travel & lodging$96411%
- Food & beverage$5,42363%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 12 | $3,360 |
| Insulet Corporation | 23 | $688 |
| Tandem Diabetes Care, Inc. | 15 | $544 |
| AbbVie | 24 | $519 |
| Novo Nordisk | 21 | $507 |
| Ascendis Pharma Endocrinology Inc | 6 | $360 |
| Lilly USA, LLC | 13 | $261 |
| Abbott | 5 | $256 |
| AstraZeneca | 9 | $206 |
| Ultragenyx Pharmaceutical Inc. | 4 | $202 |
| Eton Pharmaceuticals, Inc. | 3 | $162 |
| Lifescan, Inc. | 9 | $159 |
| Xeris Pharmaceuticals, Inc. | 8 | $145 |
| Azurity Pharmaceuticals, Inc. | 2 | $124 |
| BETA Bionics, Inc. | 6 | $110 |
| BD | 4 | $99 |
| Ipsen Biopharmaceuticals, Inc | 4 | $97 |
| Arbor Pharmaceuticals, Inc. | 5 | $94 |
| Dexcom, Inc. | 5 | $94 |
| Sanofi-aventis U.S. LLC | 5 | $91 |
| Kyowa Kirin, Inc. | 4 | $91 |
| Amneal Pharmaceuticals LLC | 5 | $89 |
| Zealand Pharma US, Inc. | 3 | $61 |
| Pfizer | 3 | $49 |
| Biomarin Pharmaceutical Inc. | 2 | $45 |
| Tolmar Pharmaceuticals, Inc. | 2 | $43 |
| Rhythm Pharmaceuticals, Inc. | 2 | $39 |
| Medtronic | 2 | $33 |
| IBSA Pharma Inc. | 2 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Tolmar, Inc. | 1 | $21 |
| Aegerion Pharmaceuticals, Inc. | 1 | $19 |
| Embecta Corp. | 1 | $18 |
| Vistapharm, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZOMACTON$3,015
- Omnipod$305
- SKYTROFA$249
- t:slim X2 Insulin Pump with Control-IQ$220
- FREESTYLE LIBRE 3$177
- CRYSVITA$125
- Sogroya$122
- Lupron Depot$115
- Triptodur$110
How this compares
$8,656 in reported general payments places this provider in the 75th percentile of 102 pediatric endocrinology providers in Florida.
Other pediatric endocrinology in Miami
- Alejandro DiazMiami$101K
- Andrea GranadosMiami$19K
- Adriana Carrillo-IreguiMiami$19K
- Janine SanchezMiami$18K
- Joshua TarkoffMiami$9K
- Omar BeckettMiami$4K
- Pedro Pagan BanchsMiami$4K
- Carmen Bustamante EscobarMiami$3K
- Jonanlis Ramirez AlcantaraMiami$2K
- Marco DanonMiami$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.